Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25613081 | 0.82 | LRRK2 (0.41) | GRM4MAPK1LRRK2BRD4TTK | |
| SCHEMBL25613060 | 0.78 | TTK (0.38) | MAPK1LRRK2TTK | |
| SCHEMBL25625653 | 0.72 | LRRK2 (0.37) | GRM4MAPK1SOS1LRRK2BRAF | |
| SCHEMBL25613062 | 0.71 | JAK3 (0.39) | MAPK1BRD4TTK | |
| SCHEMBL25613080 | 0.69 | LRRK2 (0.40) | GRM4MAPK1SOS1LRRK2 | |
| SCHEMBL25613075 | 0.69 | JAK3 (0.43) | LRRK2TTK | |
| SCHEMBL25613086 | 0.69 | JAK3 (0.46) | LRRK2TTK | |
| SCHEMBL25613082 | 0.68 | JAK3 (0.48) | LRRK2TTK | |
| SCHEMBL25613085 | 0.67 | ROCK1 (0.41) | MAPK1SOS1 | |
| SCHEMBL25613079 | 0.67 | FEN1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | FOCHON BIOSCIENCES, LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159527-A1 | COMPOUNDS AS BCL-2 INHIBITORS | BCL2, BCL2L2, BCL2L1 | GRM4 4756/4885MAPK1 2612/4885SOS1 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.